Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.285 per share.
- Aggregated Volume: 3,256.198 shares.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Sir Andrew Witty, the CEO. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan. The transaction included both personal contributions and matching shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of an insider transaction.
Investor Verification Points
- Verify the total shareholding of CEO Sir Andrew Witty following this transaction.
- Confirm the terms of the 2009 Deferred Annual Bonus Plan regarding dividend re-investment and matching shares.
- Note that this filing does not reflect the company's operational or financial performance for the period.